DNA vaccination against oncoantigens: A promise.
The emerging evidence that DNA vaccines elicit a protective immune response in rodents, dogs and cancer patients, coupled with the US Food and Drug Administration (FDA) approval of an initial DNA vaccine to treat canine tumors is beginning to close the gap between the optimistic experimental data and their difficult application in a clinical setting. Here we review a series of conceptual and biotechnological advances that are working together to make DNA vaccines targeting molecules that play important roles during cancer progression (oncoantigens) a promise with near-term clinical impact.
Aging Research Centre; G. d'Annunzio University; Chieti, Italy.
Manuela
M
Iezzi
Elena
E
Quaglino
Augusto
A
Amici
Pier-Luigi
PL
Lollini
Guido
G
Forni
Federica
F
Cavallo